Literature DB >> 32506417

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project.

Anny Camelo-Castillo1, José Miguel Rivera-Caravaca1, Francisco Marín1, Vicente Vicente2, Gregory Y H Lip3,4, Vanessa Roldán2.   

Abstract

BACKGROUND: The ABC (age, biomarkers, and clinical history)-stroke and ABC-bleeding are biomarker-based scores proposed to predict stroke and bleeding, but non-specificity of biomarkers is common, predicting different clinical events at the same time. We assessed the predictive performance of the ABC-stroke and ABC-bleeding scores, for outcomes beyond ischemic stroke and major bleeding, in a cohort of atrial fibrillation (AF) patients.
METHODS: We included AF patients stable on vitamin K antagonists for 6 months. The ABC-stroke and ABC-bleeding were calculated and the predictive values for myocardial infarction (MI), acute heart failure (HF), a composite of cardiovascular events, and all-cause deaths were compared.
RESULTS: We included 1,044 patients (49.2% male; median age 76 [71-81] years). During 6.5 (4.3-7.9) years, there were 58 (5.6%) MIs, 98 (9.4%) acute HFs, 167 (16%) cardiovascular events, and 418 (40%) all-cause deaths. There were no differences in mean ABC-stroke and ABC-bleeding scores in patients with/without MI (p = 0.367 and p = 0.286, respectively); both scores were higher in patients with acute HF, cardiovascular events, or death (all p < 0.05). Predictive performances for the ABC-stroke and ABC-bleeding scores were similar, ranging from "poor" for MI (c-indexes ∼0.54), "moderate" for acute HF and cardiovascular events (c-indexes ∼0.60 and ∼0.64, respectively), and "good" for all-cause mortality (c-indexes > 0.70). Clinical usefulness whether assessed by ABC-stroke or ABC-bleeding was similar for various primary endpoints.
CONCLUSION: In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict "sick" patients or poor prognosis overall. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32506417     DOI: 10.1055/s-0040-1712914

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.

Authors:  Kazuma Oyama; Robert P Giugliano; David D Berg; Christian T Ruff; Petr Jarolim; Minao Tang; Sabina A Murphy; Hans J Lanz; Michael A Grosso; Elliott M Antman; Eugene Braunwald; David A Morrow
Journal:  Eur Heart J       Date:  2021-05-01       Impact factor: 29.983

2.  Immunothrombosis and new-onset atrial fibrillation in the general population: the Rotterdam Study.

Authors:  Martijn J Tilly; Sven Geurts; Samantha J Donkel; M Arfan Ikram; Natasja M S de Groot; Moniek P M de Maat; Maryam Kavousi
Journal:  Clin Res Cardiol       Date:  2021-09-24       Impact factor: 5.460

3.  Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation.

Authors:  Tymon Pol; Ziad Hijazi; Johan Lindbäck; Jonas Oldgren; John H Alexander; Stuart J Connolly; John W Eikelboom; Michael D Ezekowitz; Christopher B Granger; Renato D Lopes; Salim Yusuf; Agneta Siegbahn; Lars Wallentin
Journal:  Cardiovasc Res       Date:  2022-07-20       Impact factor: 13.081

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.